Combined with anti-programmed cell PD-1 immunotherapy, AZD-UPS NPs achieved superior tumor control and survival benefit at >200-fold lower dosage than oral AZD3965 monotherapy, demonstrating that MCT1 blockade can reshape the immunosuppressive TME to potentiate checkpoint inhibition (48) (Figure 1). Here, SLC16A1 is linked to neoplasm.